Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies:

Pulmonary Circulation

RodrigoCartin-Ceba¹ 

关键词: soluble guanylate cyclase stimulator;    portal hypertension;    pulmonary arterial hypertension;   

DOI  :  10.1177/2045894018769305

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

【 授权许可】

CC BY